MedTrace Logo

Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients

NCT03489551 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2018-05-22

Study results available
· View outcomes & findings →

Summary

This research study proposes to conduct an open label, feasibility study administering prophylactic oral haldol to patients undergoing a hematopoietic stem cell transplant (HSCT).

The study will address the following research aims: 1) To demonstrate the feasibility of enrolling HSCT patients in a prophylactic medication trial, 2) To determine the tolerability of oral haldol in HSCT patients and 2) To compare rates of delirium in HSCT patients who receive prophylactic haldol with an untreated historical control group.

Conditions

  • Stem Cell Transplant Complications
  • Delirium

Interventions

DRUG

Haldol

Sponsors & Collaborators

  • American Cancer Society, Inc.

    collaborator OTHER

  • Michelle Weckmann

    lead OTHER

Principal Investigators

  • Michelle Weckmann, MD · University of Iowa

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-07-31
Completion
2013-10-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03489551 on ClinicalTrials.gov